Uniunea Europeană - greacă - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - Λευχαιμία, τριχωτό κύτταρο - Αντινεοπλασματικοί παράγοντες - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

Uniunea Europeană - greacă - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - Χοίροι - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Uniunea Europeană - greacă - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - regdanvimab - covid-19 virus infection - Άνοσοι οροί και ανοσοσφαιρίνες, - regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (covid-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Uniunea Europeană - greacă - EMA (European Medicines Agency)

gilead sciences ireland uc - sacituzumab govitecan - breast neoplasms; triple negative breast neoplasms - Αντινεοπλασματικοί παράγοντες - trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, including at least one of them for advanced disease.

Uniunea Europeană - greacă - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - Πολλαπλό μυέλωμα - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Uniunea Europeană - greacă - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - Ανοσοκατασταλτικά - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).

Uniunea Europeană - greacă - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - maribavir - Οι λοιμώξεις του κυτταρομεγαλοϊού - Αντιιικά για συστηματική χρήση - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). Πρέπει να ληφθούν υπόψη οι επίσημες οδηγίες για την κατάλληλη χρήση των αντι-ιικών παραγόντων.

Uniunea Europeană - greacă - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - Πολλαπλό μυέλωμα - Αντινεοπλασματικοί παράγοντες - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Uniunea Europeană - greacă - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - Πολλαπλό μυέλωμα - Αντινεοπλασματικοί παράγοντες - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Uniunea Europeană - greacă - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - Νεοπλάσματα του μαστού - Ενδοκρινική θεραπεία - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.